June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
COVID-19's Impact on Alzheimer's: Uncovering 2 Years of Mortality Trends
July 17th 2023This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.
Read More
COVID-19 Vaccines Bridge Socioeconomic Disparities in Pandemic Impact, CDC Study Shows
July 13th 2023This study analyzed 81 communities in Los Angeles and found that once vaccines became widely available, there was no significant difference in COVID-19 incidence between communities of varying income levels.
Read More
Can Immunomodulators Reduce Recovery Time in Patients Hospitalized With COVID-19 Pneumonia?
July 11th 2023Researchers investigated abatacept, cenicriviroc, and infliximab, but found that these medications did not significantly impact the time to recovery from COVID-19 pneumonia compared to placebo.
Read More
Novavax as a Second Dose: A Potential Game Changer for Adolescent COVID-19 Vaccination
July 6th 2023The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.
Read More
Using Comorbidities and Demographics to Predict COVID-19 Outcomes in the Midwest
June 27th 2023In Indiana, COVID-19 patients with chronic obstructive pulmonary disease, cardiovascular disease, and type 2 diabetes had significantly higher mortality rates than COVID-19 patients without these comorbidities.
Read More
Unraveling the Connection: How Air Pollution Aggravates COVID-19 and Prolongs Hospital Stays
June 23rd 2023Even low levels of air pollution make COVID-19 worse, this study found. Air pollution exposure was associated with more severe disease, longer hospitalization periods, and an increased likelihood of intensive care admission.
Read More
Innovative ABNCoV2 COVID-19 Booster Vaccine Induces Long-Lasting Protection
June 20th 2023ABNCoV2, a non-adjuvanted COVID-19 booster vaccine by Bavarian Nordic, demonstrates promising results in phase 2 trials. The vaccine generates strong immune responses, neutralizing multiple variants of concern, including Beta, Delta, and Omicron.
Read More
Online Harassment of Physicians and Scientists During the COVID-19 Pandemic
June 20th 2023This past weekend, vaccine scientist and physician Peter Hotez, MD, PhD, was stalked outside his home after facing online scrutiny from Twitter CEO Elon Musk and controversial podcaster Joe Rogan. His story is severe, but Hotez is far from the first health advocate to be harassed online since the COVID-19 pandemic.
Read More
COVID-19 Rebound Found More in Hospitalized Patients With Existing Health Problems
June 9th 2023A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.
Read More
COVID-19 Public Health Emergency Is Over. What Have We Learned?
June 7th 2023As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.
Read More
2 Commerce Drive
Cranbury, NJ 08512